CFO departure
Allogene Therapeutics, Inc. discloses CFO departure: Geoffrey Parker
Allogene Therapeutics, Inc. reported in a Form 8-K filed September 2, 2026 a change involving its Chief Financial Officer, Geoffrey Parker, effective November 6, 2026. The filing's own words are quoted below.
In the filing's words
On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Allogene Therapeutics, Inc. (ALLO) |
|---|---|
| Event | Departure |
| Outgoing | Geoffrey Parker |
| Effective | November 6, 2026 |
| 8-K filed | September 2, 2026 |
| SEC CIK | 0001737287 |
Allogene Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed September 2, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Geoffrey Parker? Send a correction with the primary source.